H.C. Wainwright initiates coverage for Ionis Pharma with 'buy' rating citing pending drug launches
07/04/2025 14:57
** Brokerage H.C. Wainwright starts coverage on drugmaker Ionis Pharmaceuticals IONS.O with "buy" rating and a PT of $45
** Brokerage sees upside in IONS' pending commercial launches, including Tryngolza for lowering triglycerides and Wainua for transthyretin-mediated amyloidosis (ATTR)
** Brokerage estimates that Tryngolza could serve 2.3 million patients in the U.S. and become a growth driver for the company, potentially generating $1.8 billion in sales by 2033
** 17 out of 26 brokerages rate the stock "buy" or higher, 8 rate "hold" and 1 rate "sell" and their median PT is $60 as per LSEG data
** As of last close, IONS stock down 22.5% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
Recent news on Ionis Pharmaceuticals
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S.
Brief: Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia
Brief: FDA Approves Treatment To Reduce Risk Of Acute Pancreatitis In Adults With Severe Hypertriglyceridemia
Brief: Ionis Announces Appointment Of Ludwig Hantson, Ph.D. To Board Of Directors